Sunshine Biopharma (SBFM) AI Stock Analysis

• Market Cap: $5.42M
• Dividend Yield: N/A
• Average Volume (3M): 37.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 61.94%
• EPS Growth: 93.40%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 71
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -155.59
• Shares Outstanding: 2,708,341
• 10 Day Avg. Volume: 25,803
• 30 Day Avg. Volume: 37,978
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.19
• Price to Cash Flow (P/CF): -1.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Sunshine Biopharma is showing strong revenue growth, which is a positive sign in the pharmaceuticals industry. However, ongoing challenges with profitability, cash flow management, and weak technical indicators weigh heavily on the stock's performance. The low valuation score, due to a negative P/E ratio and lack of dividends, also detracts from its attractiveness. To improve the stock score, the company needs to address its operational efficiencies and liquidity issues.

Sunshine Biopharma Business Overview & Revenue Model

Company Description

Sunshine Biopharma (SBFM) is a pharmaceutical company engaged in the development and commercialization of oncology and antiviral drugs. The company focuses on creating innovative treatment solutions for various cancers and viral infections. Sunshine Biopharma aims to improve patient outcomes by leveraging advanced scientific research and proprietary technologies in the biotechnology sector.

How the Company Makes Money

Sunshine Biopharma makes money primarily through the development and sale of pharmaceutical products, including proprietary drugs targeting cancer and viral infections. The company generates revenue by licensing its drug candidates to larger pharmaceutical firms, which may involve upfront payments, milestone payments, and royalties on sales. Additionally, Sunshine Biopharma may engage in strategic partnerships and collaborations with other biotechnology and pharmaceutical companies, which can provide funding and shared resources for research and development efforts. The company's earnings are also influenced by its ability to successfully navigate regulatory approvals and bring its products to market.

Sunshine Biopharma Financial Statement Overview

Summary

Sunshine Biopharma is experiencing significant revenue growth, showcasing potential in the pharmaceuticals industry, yet continues to face challenges with profitability and cash flow management. The strong equity base and low leverage are positives, providing a buffer against operational risks. However, the company needs to focus on improving operational efficiencies and cash flow generation to enhance its financial health.

Income Statement

Sunshine Biopharma's revenue growth has been strong, showcasing a significant increase from $43,456,03 in 2022 to $32,959,492 in TTM, indicating a robust growth trajectory. However, the company continues to operate at a net loss with a negative net profit margin, suggesting ongoing profitability challenges. Both EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a healthy equity base with stockholders' equity of $25,039,312 in TTM, giving an impressive equity ratio of 83.3%. The debt-to-equity ratio is low at 0.02, indicating a conservative leverage position. However, the company needs to manage its liabilities prudently to ensure financial stability.

Cash Flow

Sunshine Biopharma's cash flow presents challenges, as indicated by negative free cash flow of $-13,906,278 in TTM and negative operating cash flow. The absence of free cash flow growth and a negative operating cash flow to net income ratio highlight liquidity pressures, potentially affecting future operations.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
32.96M	24.09M	4.35M	228.43K	71.41K	21.12K
	Gross Profit
9.94M	8.34M	1.70M	110.60K	45.56K	10.07K
	EBIT
-4.62M	-4.79M	-8.67M	-2.44M	-576.87K	-641.64K
	EBITDA
-4.02M	-3.82M	-26.45M	-12.09M	-2.60M	-948.38K
	Net Income Common Stockholders
-4.23M	-4.51M	-26.74M	-12.77M	-897.68K	-1.46M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
95.13K	16.29M	21.83M	2.05M	989.89K	40.50K
	Total Assets
1.25M	27.35M	29.24M	2.20M	1.05M	98.14K
	Total Debt
1.24M	657.71K	4.27M	1.90M	1.91M	715.57K
	Net Debt
1.14M	-15.63M	-17.55M	-145.17K	923.23K	675.07K
	Total Liabilities
1.46M	6.14M	7.62M	1.99M	2.00M	833.53K
	Stockholders Equity
-211.77K	21.21M	21.63M	211.66K	-954.84K	-735.38K
Cash Flow		Free Cash Flow
-13.91M	-9.56M	-5.55M	-1.83M	-658.49K	-496.66K
	Operating Cash Flow
-11.81M	-8.78M	-5.25M	-1.83M	-657.30K	-495.80K
	Investing Cash Flow
-2.06M	-656.15K	-14.62M	0.00	-1.19K	-15.28K
	Financing Cash Flow
7.20M	3.43M	39.47M	2.90M	1.61M	442.25K

Sunshine Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBFM, the sentiment is Negative. The current price of 2 is below the 20-day moving average (MA) of 2.16, below the 50-day MA of 2.44, and below the 200-day MA of 3.50, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 37.49 is Neutral, neither overbought nor oversold. The STOCH value of 26.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SBFM.

Sunshine Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SBFM	52 Neutral	$5.42M	―	-17.98%	―	61.94%	93.40%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	19.94%	1.20%
ATNM	45 Neutral	$56.46M	―	-100.05%	―	―	26.97%
AVTX	45 Neutral	$90.28M	―	-50.06%	―	-77.09%	63.49%
BTAI	39 Underperform	$6.98M	―	82.91%	―	64.20%	73.71%
ACHV	37 Underperform	$96.42M	―	-409.51%	―	―	19.70%
CYCC	36 Underperform	$61.99M	―	-807.39%	―	-80.98%	62.27%

Sunshine Biopharma Corporate Events

Sunshine Biopharma Strengthens Leadership with New Executive Agreements

Sunshine Biopharma Inc. has solidified its leadership team with new employment agreements for its top executives, effective January 1, 2024. Dr. Steve N. Slilaty, CEO, Camille Sebaaly, CFO, and Dr. Abderrazzak Merzouki, COO, will receive annual salary hikes tied to inflation or a minimum increase, whichever is higher. In case of termination without cause, substantial severance packages are promised, ensuring stability and confidence in the company’s future growth strategies.